X

Drug Profile

Prostate cancer DNA vaccine - Cellectis/Karolinska Institute

Alternative Names: pVAXrcPSAv53l

Latest Information Update: 22 Sep 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cyto Pulse Sciences; Karolinska Institute
Developer Cellectis; Karolinska Institute
Class Cancer vaccines; DNA vaccines; Gene therapies
Mechanism of Action Gene transference; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Prostate cancer

Most Recent Events

31 Dec 2008 Phase-I/II clinical trials in Prostate cancer in Sweden (Intradermal)
11 Oct 2008 The Swedish Medical Products Agency approves clinical trial application for DNA vaccine in Prostate cancer
17 May 2007 Preclinical data added to the Cancer pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com